Phages for treatment of Staphylococcus aureus infection

Bibliographic Information
Authors: Samir S.
Journal: Progress in Molecular Biology and Translational Science
Publisher: Elsevier B.V.
Publication Date: 2023
Volume / Issue: Volume 200
Pages: 275–302
ISSN: 18771173
DOI: 10.1016/bs.pmbts.2023.03.027
Scopus: View on Scopus
PubMed: 37739558
Document Type: Book chapter
Authors and Affiliations
Samir S., Department of Biochemistry and Molecular Biology, Theodor Bilharz Research Institute, Giza, Egypt
Abstract
Combating multi-drug resistant bacterial infections should be a universal urgency. The gram- positive Staphylococcus aureus (S. aureus) bacteria are generally harmless; healthy people frequently have them on their skin and nose. These bacteria, for the most part, produce no difficulties or only minor skin diseases. Antibiotics and cleansing of the affected region are usually the treatments of choice. S. aureus can become virulent causing serious infections that may lead to pustules to sepsis or death. Normally, it is thought that antibiotics may solve problems concerning bacterial infection; but unfortunately, Staphylococci have evolved mechanisms to resist drugs. Methicillin-Resistant Staphylococcus aureus (MRSA); both in hospitals and in the community, infections are evolving into dangerous pathogens. Health care practitioners may need to use antibiotics with more adverse effects to treat antibiotic-resistant S. aureus infections. Amid existing efforts to resolve this problem, phage therapy proposes a hopeful alternate to face Staphylococcal infections. When the majority of antibiotics have failed to treat infections caused by multidrug-resistant bacteria, such as methicillin- and vancomycin-resistant S. aureus, phage therapy may be an option. Here, we appraise the potential efficacy, current knowledge on bacteriophages for S. aureus, experimental research and information on their clinical application, and limitations of phage therapy for S. aureus infections. © 2023
Keywords
animal models; bacteriophages; Drug resistance; host range; phage cocktails; phage genome; Staphylococcus aureus; Anti-Bacterial Agents; Humans; Methicillin-Resistant Staphylococcus aureus; Staphylococcal Infections; antiinfective agent; antibiotic therapy; bacterial genome; bacteriophage; bacteriophage ab sa01; bacteriophage aptc c sa01; bacteriophage k; bacteriophage phb22a; bacteriophage phb25a; bacteriophage phb38a; bacteriophage phb40a; bacteriophage v1sa19; bacteriophage v1sa20; bacteriophage v1sa22; bacterium culture; bacterium identification; bone infection; cardiovascular infection; clinical trial (topic); drug efficacy; drug safety; experimental study; genetic engineering; genomics; human; infectious arthritis; invertebrate model; lung infection; Microvirus; mouse model; Myoviridae; nonhuman; phage jd219; phage therapy; plankton; Podoviridae; rabbit model; respiratory tract infection; Siphoviridae; skin infection; soft tissue infection; Staphylococcus aureus infection; methicillin resistant Staphylococcus aureus; Staphylococcus infection
Citation Information
Scopus Citations: 5
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
